The European drug landscape is at a critical juncture. EUDA's expanded mandate, the MFF 2028–2034 negotiations, and the upcoming EU Drugs Strategy renewal create a unique window to align European research investments with the most pressing needs identified by Member States, researchers, practitioners, and people with lived experience. PPMI | Part of the Verian Group has been contracted by the EU Drugs Agency to develop a transparent, replicable process for multi-stakeholder research prioritisation, one that will directly shape Horizon Europe investments and EUDA's own research agenda through 2030 and beyond.
Adapting the internationally recognised James Lind Alliance framework, we will combine AI-supported evidence synthesis with inclusive stakeholder engagement across all 24 EU languages. Deliberative workshops at Lisbon Addictions 2027, Europe's largest addiction research conference, and a modified Delphi consensus process ensure priorities reflect both rigorous evidence and diverse stakeholder perspectives.
This project will deliver both immediate priorities and long-term infrastructure, creating value for multiple stakeholders across the European drug policy ecosystem:
- For EUDA: Actionable Top-10 research priorities and sustainable infrastructure transforming research prioritisation from external consultancy into embedded internal capability
- For Horizon Europe and Member States: Evidence-based priorities guiding strategic allocation of €95.5 billion in research investments
- For the field: A transparent, inclusive model for research prioritisation that amplifies the voices of practitioners, civil society, and people with lived experience alongside policymakers and researchers
